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Bacterial meningitis is characterized by an inﬂammatory reaction to the invading pathogens that can
ultimately lead to sensorineural hearing loss, permanent brain injury, or death. The matrix metalloproteinases
(MMPs) and tumor necrosis factor alpha-converting enzyme (TACE) are key mediators that promote inﬂam-
mation, blood-brain barrier disruption, and brain injury in bacterial meningitis. Doxycycline is a clinically
used antibiotic with anti-inﬂammatory effects that lead to reduced cytokine release and the inhibition of
MMPs. Here, doxycycline inhibited TACE with a 50% inhibitory dose of 74 M in vitro and reduced the
amount of tumor necrosis factor alpha released into the cerebrospinal ﬂuid by 90% in vivo. In an infant rat
model of pneumococcal meningitis, a single dose of doxycycline (30 mg/kg) given as adjuvant therapy in
addition to ceftriaxone 18 h after infection signiﬁcantly reduced the mortality, the blood-brain barrier dis-
ruption, and the extent of cortical brain injury. Adjuvant doxycycline (30 mg/kg given subcutaneously once
daily for 4 days) also attenuated hearing loss, as assessed by auditory brainstem response audiometry, and
neuronal death in the cochlear spiral ganglion at 3 weeks after infection. Thus, doxycycline, probably as a
result of its anti-inﬂammatory properties, had broad beneﬁcial effects in the brain and the cochlea and
improved survival in this model of pneumococcal meningitis in infant rats.
Pneumococcal meningitis has a high level of mortality (up to
30%), and brain and/or cochlear damage occurs in up to 50%
of the survivors (2). Inﬂammatory mediators, such as tumor
necrosis factor alpha (TNF-) and matrix metalloproteinases
(MMPs), are produced during the host response to bacteria
and contribute to the pathophysiology that can ultimately lead
to death, brain damage, and hearing impairment (23, 26, 29,
36). The role of cytokines and MMPs in the pathophysiology of
the cochlear damage associated with pneumococcal meningitis
is still unknown. However, it has been demonstrated that
MMPs are constitutively expressed at high levels in the cochlea
(8) and that in meningitis pneumococci and polymorphonu-
clear leukocytes (PMNs) extend from the cerebrospinal ﬂuid
(CSF) to the perilymph via the cochlear aqueduct (5).
Tetracyclines are bacteriostatic agents with broad-spectrum
antimicrobial activity (3). Doxycycline is a semisynthetic, long-
acting, second-generation tetracycline which is absorbed rap-
idly and penetrates well into the brain and CSF (48). Doxycy-
cline has been shown to have anti-inﬂammatory effects that are
separate and distinct from its antimicrobial action (13, 16, 35,
43). These effects include the reduction of cytokine release and
the inhibition of MMPs (7, 38). Experimental and clinical
studies have indicated that treatment with doxycycline may be
beneﬁcial in inﬂammatory diseases associated with excessive
MMP activity (7, 13, 35).
In pneumococcal meningitis massive subarachnoid and ven-
tricular space inﬂammation is triggered by the presence of
bacteria in the CSF space (7, 13, 35). Cytokines, such as
TNF-, trigger a cascade of inﬂammatory mediators, including
MMPs. In turn, MMPs and related metalloproteinases can act
as sheddases or convertases as they transform membrane-
bound cytokines, cytokine receptors, and adhesion molecules
into their soluble forms (27). TNF--converting enzyme (TACE),
a membrane protein that contains a disintegrin and a metal-
loproteinase domain, is a highly efﬁcient sheddase of TNF-
and TNF receptors and plays an integral part in the inﬂam-
matory network of MMPs and cytokines in bacterial meningitis
(17, 23).
Pharmacologic inhibition of MMPs and TACE has beneﬁ-
cial effects in experimental models of bacterial meningitis. The
hydroxamic acid-based MMP inhibitor BB-94 prevented the
extravasation of Evans blue, an indicator of blood-brain barrier
(BBB) permeability, in a model of meningococcal meningitis
(36). Another MMP inhibitor, GM-6001, reduced cortical neu-
ronal injury in an infant rat model of pneumococcal meningitis
(24). Treatment with BB-1101, an inhibitor of both MMPs and
TACE, reduced the concentration of TNF- in the CSF, re-
duced mortality, and attenuated brain injury in experimental
pneumococcal meningitis (23).
While these drugs have not been tested in clinical studies,
doxycycline is a relatively inexpensive drug with a well-charac-
terized clinical safety proﬁle. Here we demonstrate that doxy-
cycline potently inhibits TACE in vitro and reduces TNF-
release into the CSF in a model of sterile meningitis. Given as
an adjuvant with a beta-lactam antibiotic for pneumococcal
meningitis, doxycycline reduced mortality, protected the BBB,
and reduced injury in the cerebral cortex. Doxycycline also
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attenuated neuronal death in the cochlear spinal ganglion,
which correlated with attenuation of hearing loss.
MATERIALS AND METHODS
Model of sterile meningitis. A model of sterile meningitis was used to exclude
the effects of antimicrobial mechanisms on inﬂammatory parameters. The non-
encapsulated Streptococcus pneumoniae mutant R6 was grown at 37°C in brain
heart infusion (BHI) to the mid-logarithmic phase, washed with sterile saline,
and resuspended in saline at a concentration of 5  1010 CFU/ml. The bacteria
were then heat inactivated at 80°C for 20 min, and 10 l of the suspension
containing heat-inactivated R6 pneumococci (hiR6) was injected intracisternally
into nursing Wistar rats (n 14) on postnatal day 11 using a 32-gauge needle. At
3, 6, 12, and 24 h after induction of sterile meningitis, CSF was obtained by
puncture of the cisterna magna to determine inﬂammatory parameters, as de-
scribed below.
Model of meningitis with live pneumococci. Nursing Wistar rats were injected
intracisternally on postnatal day 11 with 10 l of saline containing 2.5  106 
1.5  106 CFU/ml S. pneumoniae as described previously (23). At 18, 24, and
40 h after infection, all animals were assessed clinically as described elsewhere
(23), and CSF was obtained from the cisterna magna to document infection and
to determine the number of bacteria by plating serial dilutions of CSF on blood
agar plates. If incubation of 5 l of undiluted CSF did not result in growth of
bacteria, the CSF was considered to be sterile. The detection limit for bacteria in
the CSF was 200 CFU/ml. Immediately after CSF was removed 18 h after
infection, antibiotic treatment with 100 mg/kg ceftriaxone (Roche Pharma,
Reinach, Switzerland) given subcutaneously (s.c.) was initiated.
All animal studies were approved by the Animal Care and Experimentation
Committee of the Canton of Bern, Switzerland, and were performed using
National Institutes of Health guidelines for animal experiments.
Treatment regimens. For sterile meningitis, animals received doxycycline (30
mg/kg given s.c.; n  7; Vibraveno¨s; Pﬁzer AG, Zurich, Switzerland) or an equal
volume of saline (250 l; n 7) at the time of intracisternal injection of the hiR6
(pretreatment study). This dose has been shown previously to suppress cerebral
MMP-9 activity in rodents and to reduce ischemic brain damage (9, 22).
To study the histopathological outcome posttreatment, we used a model with
live bacteria. Beginning 18 h after infection, all animals (n  132) received
ceftriaxone (100 mg/kg given intraperitoneally [i.p.] every 12 h) and were ran-
domized for treatment with a single dose of doxycycline (30 mg/kg given s.c.; n 
67) or with the same volume of saline (250 l; n  65). Treatments with
ceftriaxone and doxycycline were initiated within 1 min of each other. The
additives used in the formulation of doxycycline (polyvinylpyrrolidone and
2-amionethanol) are ingredients that are commonly used for preparation of
pharmaceutical products, and no neuroprotective effects of these compounds
have been reported. At 18, 24, and 40 h after infection, all animals were assessed
clinically, and CSF was obtained from the cisterna magna to quantify the bac-
teria. At 40 h after infection, the surviving animals were sacriﬁced, and brain
damage and BBB integrity were assessed as described below.
To assess cochlear damage, animals were infected (n  34) and randomized
for treatment with doxycycline (30 mg/kg given s.c. every 24 h; n  20) or with
the same volume of saline (n 14). Mock-infected animals (n 9) that received
doxycycline were included in the study. All animals (n  43) were treated with
ceftriaxone (100 mg/kg given i.p. every 12 h). This treatment schedule was
maintained for 4 days, starting 18 h after infection. At 3 weeks after infection,
animals were sacriﬁced, and the density of type I neurons in the spiral ganglion
was assessed by histomorphological analysis of cochlear sections (one randomly
chosen cochlea per animal). The auditory brainstem responses (ABR) were
measured in both ears of a subset of randomly chosen animals just before they
were sacriﬁced (n  16, n  13, and n  5 for the doxycycline, saline, and
mock-infected groups, respectively).
Pharmacologic studies. The pharmacokinetics and the penetration of doxycy-
cline into the CSF in animals with bacterial meningitis were studied by deter-
mining drug levels in the plasma and in the CSF 2, 4, 6, 8, and 10 h after s.c.
injection of a single dose of doxycycline (30 mg/kg) given 18 h after infection of
a separate group of animals (n  15). Drug concentrations were determined by
the agar diffusion method (12). The standard curve for plasma was generated
with rat plasma, while the standard curve for CSF was generated with saline
containing 10% rat plasma. Escherichia coli ATCC 10536 was used as the indi-
cator strain.
Histopathology. To assess the effect of doxycycline on brain damage in animals
with pneumococcal meningitis, the brains were evaluated histomorphologically
40 h after infection as described previously (23). Brieﬂy, animals were perfused
with 4% paraformaldehyde, and the brains were removed from the skulls and
postﬁxed for 4 h in paraformaldehyde. The extent of cortical brain damage was
assessed quantitatively, and the results were expressed as the percentage of the
total cortical area, as described in detail previously (24). Neurons in the dentate
granule layer of the hippocampus with a nuclear morphology typical of apoptosis
were counted and scored, and the average score per animal was calculated from
the data obtained for the sections evaluated (24). Animals that died before
40 h were excluded from the analysis. The evaluations were performed by an
investigator blinded to the clinical, microbiological, and treatment data for
the animals.
Histopathology of the cochlea. To determine the density of type I neurons in
the spiral ganglion, the region of the temporal bone containing the cochlea was
dissected from the skull and decalciﬁed for 10 days in phosphate-buffered saline
containing 120 mM EDTA and 0.1% sodium azide. One cochlea of each animal
was embedded in parafﬁn, and the six most mid-modiolar sections (thickness, 10
m) were mounted on a glass slide and stained with toluidine blue. The speci-
mens were analyzed with a light microscope, and the images were digitized. The
outline of the Rosenthal’s canal was traced using the NIH Image program
(version 1.61; U.S. National Institutes of Health, Bethesda, MD). The type I
neurons in 10 proﬁles of the Rosenthal’s canal, from the base to the apex of the
cochlea, were counted. The results were expressed as the density of type I
neurons per 104 m2 (40).
ABR measurements. Using inactin-anesthetized animals, ABR were recorded
in an audiometric room (model AC-1 chamber; Industrial Acoustics Company,
Niederkru¨chten, Germany) for both ears in response to click stimulation (pre-
sentation rate, 20 clicks/s). Subdermal needle electrodes were placed in the
mastoid of the ear tested (active), at the vertex (reference), and in the cervical
neck muscles (ground). The sound stimulus consisted of 100-s square wave
impulses synthesized digitally using the SigGen32 software (System II; Tucker-
Davis Technologies, Alachua, FL), fed into a programmable attenuator, and
after D/A conversion transduced by a speaker (2405H ultra-high-frequency driver;
JBL Professional, Northridge, CA) located 4 cm from the pinna. The system was
calibrated with a sound level meter (2231 modular precision sound level meter;
Bru¨el & Kjær, Nærum, Denmark) by measuring with a 0.5-in. microphone (type
4189; Bru¨el & Kjær, Nærum, Denmark) the maximum peak level (expressed in
dB SPL; reference pressure, 20 Pa) emitted by the speaker when it was driven
by a square wave impulse. ABR were ampliﬁed (103), band-pass ﬁltered between
100 Hz and 3 kHz (model 1201low-noise preampliﬁer; Ithaco, Ithaca, NY), and
averaged (n  500) during a 12-ms window with the data acquisition software
BioSig32 (System II; Tucker-Davis Technologies, Alachua, FL). The intensity of
the click stimulus was reduced from 110 to 0 dB SPL in 10-dB steps. The hearing
threshold was deﬁned as the lowest intensity which induced the appearance of a
visually detectable ﬁrst peak.
In vitro time kill assay for pneumococci. Pneumococci were cultured in BHI
to an optical density at 590 nm of 0.3 and then diluted 40-fold in BHI. The effects
of doxycycline (1 MIC), ceftriaxone (4 MIC), and a combination of doxycy-
cline (1 MIC) and ceftriaxone (4 MIC) were then assessed by quantitative
determination of bacterial numbers by culturing serial dilutions obtained at 2, 4,
and 6 h.
TACE inhibition assay. Inhibition of TACE by doxycycline was assessed using
recombinant human TACE and a ﬂuorescence-quenched peptide substrate (21).
Inﬂammatory parameters. Soluble TNF- in the CSF was measured by a rat
TNF- immunoassay (Quantikine; R&D Systems, Minneapolis, MN). CSF sam-
ples were centrifuged, the supernatants were diluted 1:50 in dilution buffer, and
the assay was performed by following the manufacturer’s instructions. PMNs in
the CSF were counted in a hematocytometer chamber after 10-fold dilution in
0.4% Tu¨rk’s solution.
Assessment of BBB integrity. To quantify changes in BBB integrity, we as-
sessed the levels of extravasated serum albumin in the cerebral cortex in a subset
of animals. At 40 h after infection, doxycycline-treated animals (n  14) and
saline-treated animals (n  14) were perfused with phosphate-buffered saline.
The frontal pole of the brain was removed and homogenized (1:6, wt/vol) in 20
mM HEPES buffer (pH 7.4) containing 1 mM acetic acid, 0.1 mM dithiothreitol,
0.1% Triton X-100, 0.2 mM phenylmethylsulfonyl ﬂuoride, 10 g/ml pepstatin,
10 g/ml aprotinin, and 10 g/ml leupeptin. Protein concentrations were deter-
mined by the Pierce bicinchoninic acid assay (Pierce, Rockford, IL). Albumin
concentrations in cortex homogenates were determined with a rat-speciﬁc albu-
min enzyme immunoassay kit (Nephrat; Exocell Inc., Philadelphia, PA).
Statistics. Normally distributed variables were expressed as means  standard
deviations unless indicated otherwise and were compared using one-way analysis
of variance, followed by the unpaired Student t test. Variables that were not
normally distributed were compared by using the Kruskal-Wallis test. When the
latter test yielded a statistically signiﬁcant value (P  0.05), a pairwise compar-
ison was done using the two-tailed nonparametric Mann-Whitney U test. Sur-
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tested by assuming Gaussian populations (Pearson).
RESULTS
Inhibition of TNF- release by doxycycline. Doxycycline in-
hibited recombinant human TACE, and the 50% inhibitory
concentration (IC50) was 74  4 M in vitro. In animals with
sterile meningitis, intracisternal injection of hiR6 resulted in
strong release of TNF- into the CSF after 3 h (Fig. 1A). The
TNF- concentrations were comparable to those in meningitis
models obtained by using live pneumococci (23). The TNF-
levels normalized within 12 h after injection of hiR6. Pretreat-
ment of the animals with 30 mg/kg doxycycline administered
i.p. reduced the amount of TNF- released by 90% (Fig. 1A).
The release of TNF- caused by hiR6 was followed by an inﬂux
of PMNs into the CSF, which peaked 12 h after injection of
hiR6 and disappeared by 24 h (Fig. 1B). Pretreatment with 30
mg/kg doxycycline reduced the number of PMNs in CSF by
56% (Fig. 1B). We concluded that reduction of the inﬂamma-
tion in the CSF resulting from doxycycline treatment is mod-
ulated by strong inhibition of early TNF- release, probably as
a result of the inhibitory effect of doxycycline on the activity
of TACE.
Pharmacokinetic study. The concentrations of doxycycline
after s.c. administration of 30 mg/kg peaked in plasma and CSF
4 h after administration (50 24 M in plasma and 16 8 M
in CSF). The ratio of the area under the curve for CSF to the
area under the curve for plasma 10 h after administration was
28.4% (Fig. 2).
Effect of doxycycline on bacterial killing by ceftriaxone. One
concern regarding the use of doxycycline as adjuvant therapy
for pneumococcal meningitis is the potential antagonistic effect
with bactericidal antibiotics. Indeed, in vitro the killing of
pneumococci by ceftriaxone at a concentration that was four
times the MIC was partially antagonized by administration
along with doxycycline (1 MIC) (Fig. 3A). In animals with
experimental meningitis, however, combined therapy with
doxycycline (30 mg/kg) and ceftriaxone (100 mg/kg) and ther-
apy with ceftriaxone (100 mg/kg) alone did not result in sig-
niﬁcantly different bacterial titers in the CSF 6 h after the
initiation of antibiotic treatment (CSF was sterile in 6/23 and
7/21 animals, respectively [not signiﬁcantly different]; 8.0 
105  15.0  105 CFU/ml [n  23] and 3.2  105  6.7  105
CFU/ml [n  21], respectively [not signiﬁcantly different]).
Amounts of CSF sufﬁcient for assessment of quantitative bac-
terial titers were not obtained from all animals. At 40 h, CSF
samples from animals in the two treatment groups were sterile
(Fig. 3B). Thus, the antagonism observed in vitro seems to
have little relevance for bacterial clearance in vivo.
Reduction in mortality, BBB leakage, cortical brain injury,
and neuronal loss in the cochlear spiral ganglion. In the post-
treatment study, which more closely reﬂected the clinical situ-
ation, the combined treatment with doxycycline and ceftriax-
one signiﬁcantly improved survival within 40 h after infection
compared with treatment with ceftriaxone alone; the mortality
rates were 20% for doxycycline plus ceftriaxone and 48% for
saline plus ceftriaxone (P  0.02) (Fig. 4A). Furthermore,
FIG. 1. Anti-inﬂammatory effect of doxycycline in animals with
sterile meningitis. (A) Intracisternal injection of hiR6 resulted in re-
lease of large amounts of TNF- into the CSF after 3 h (gray circles).
Pretreatment with doxycycline reduced the amount of TNF- released
by 90% (open circles) (the asterisk indicates that the P value is 0.03
for a comparison with saline-treated animals at 3 h after infection [n
3 for each group]). (B) Inﬂux of PMNs into the CSF after injection of
hiR6. Pretreatment with doxycycline signiﬁcantly reduced the number
of PMNs in CSF by 56% (the asterisk indicates that the P value is
0.05 for a comparison with saline-treated animals at 12 h after in-
fection [n  4 for each group]). WBC, white blood cells.
FIG. 2. Pharmacokinetics of doxycycline. Doxycycline at a dose of
30 mg/kg was administered 18 h after infection.
FIG. 3. Interaction of ceftriaxone and doxycycline in vitro and in
vivo. (A) In vitro time kill curves for S. pneumoniae. The bacteriostatic
antibiotic doxycycline (1 MIC) inhibited growth of pneumococci.
The bactericidal antibiotic ceftriaxone (4 MIC) rapidly killed the
pneumococci. The combination of doxycycline (1 MIC) and ceftri-
axone (4MIC) (Cef.Dox.) exhibited in vitro antagonism. (B) Bac-
terial CSF titers in vivo at 0, 18, 24, and 40 h after infection with live
pneumococci. At 24 h (6 h after the initiation of antibiotic treatment)
combined therapy with doxycycline (30 mg/kg) and ceftriaxone (100
mg/kg) (Cef.  Dox.) and therapy with ceftriaxone (100 mg/kg) alone
did not result in signiﬁcantly different bacterial titers in the CSF (8.0
105  15.0  105 CFU/ml [n  23] and 3.2  105  6.7  105 CFU/ml
[n  21], respectively [not signiﬁcantly different]). At 40 h after infec-
tion, CSF samples from all animals were sterile.
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adjuvant doxycycline reduced the amount of albumin extrava-
sated into the cerebral cortex (7.9  0.9 g cortical albu-
min/mg total protein for doxycycline plus ceftriaxone versus
12.7  2.0 g cortical albumin/mg total protein for ceftriaxone
plus saline[P  0.04]), indicating that there was signiﬁcant
reduction of the BBB disruption associated with bacterial men-
ingitis. Also, adjuvant doxycycline signiﬁcantly reduced the ex-
tent of cortical necrosis observed 40 h after infection (0 to
2.8% of the cortex damaged for doxycycline plus ceftriaxone
versus 0 to 26.9% of the cortex damaged for saline plus ceftri-
FIG. 4. Effect of doxycycline on survival and neuronal damage in the cortex and the cochlear spinal ganglion. (A) When doxycycline was given
18 h after infection in addition to the antibiotic ceftriaxone (n  67), it signiﬁcantly improved the survival compared to treatment with antibiotics
alone (Saline) (n  65). (B) Adjuvant doxycycline (n  67) (open circles) signiﬁcantly reduced the extent of neuronal injury in the cerebral cortex
compared with the extent of neuronal injury with saline (n  65) (gray circles). (C) Density of type I neurons in the Rosenthal’s canal at 3 weeks
after the infection. Adjuvant doxycycline (30 mg/kg given s.c. every 24 h for 4 days; n  20) signiﬁcantly reduced the neuronal loss in the cochlear
spiral ganglion compared to the neuronal loss with saline (n  14).
FIG. 5. (A to C) Brain histology of infant rats with pneumococcal meningitis 40 h after infection. (A and B) Whole-brain sections of the animals
with the most cortical injury in the group treated with ceftriaxone alone (A) and the group treated with ceftriaxone and doxycycline (B). Areas
where there was markedly reduced neuronal density were wedge shaped (arrowheads). The sections were stained with cresyl violet. Original
magniﬁcation,5; scale bar 1 mm. (C) Focus of cortical neuronal loss (upper left) with morphological features of necrosis, including cell swelling
and fading of the cytoarchitecture. There was sharp demarcation from preserved neurons (lower right). The section was stained with cresyl violet.
Original magniﬁcation, 200; scale bar  50 m. (D to F) Histology of the Rosenthal’s canal in the middle turn of the cochlea 3 weeks after
infection. (D) In a mock-infected animal type I neurons (arrowhead) were present in the cochlear spiral ganglion. (E) In an animal that recovered
from experimental pneumococcal meningitis type I neurons (arrowhead) were reduced. (F) Adjuvant doxycycline (30 mg/kg given s.c. every 24 h
for 4 days) attenuated the loss of type I neurons. Scale bar  100 m.
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axone (P  0.02) (Fig. 4B and 5A to C). Apoptosis in the
dentate gyrus of the hippocampus was not affected by doxycy-
cline treatment (data not shown). Pneumococcal meningitis
caused signiﬁcant loss of type I neurons in the spiral ganglion,
as determined 3 weeks after the infection (results are ex-
pressed as the density of type I neurons per 104 m2: 30.66 
2.19 for mock-infected animals versus 15.02 1.87 for animals
that were infected and treated with ceftriaxone plus saline [P
0.0001]) (data not shown). Adjuvant doxycycline signiﬁcantly
attenuated the loss of type I neurons in infected animals (22.42
 1.66 for animals that were treated with doxycycline plus
ceftriaxone versus 15.02  1.87 for animals that were treated
with saline plus ceftriaxone [P 0.005]) (Fig. 4C and 5D to F),
although there was a signiﬁcant difference compared to mock-
infected animals (P  0.01) (data not shown).
ABR measurements. Bacterial meningitis caused a repro-
ducible increase in the click-induced ABR thresholds (about
60 dB SPL) determined 3 weeks after infection (103.1  2.47
for saline-treated animals versus 39.0 3.48 for mock-infected
animals [P  0.0001]). Adjunctive doxycycline slightly but sig-
niﬁcantly attenuated the increase in the ABR thresholds in
infected animals (94.06  2.87 for doxycycline-treated animals
versus 103.1  2.47 for saline-treated animals [P  0.02]).
DISCUSSION
In the present study performed in a rat model of pneumo-
coccal meningitis, when the antibiotic doxycycline was given in
addition to ceftriaxone, it decreased the mortality and reduced
the damage to the brains and cochleas of the surviving animals.
In pneumococcal meningitis, bacteriolytic antimicrobial agents
(e.g., ceftriaxone) cause the release of bacterial cell wall prod-
ucts, which are highly proinﬂammatory (44). Antibiotic thera-
pies using less bacteriolytic agents for bacterial meningitis have
been proposed previously (31, 42). Indeed, treatment with
rifampin followed by ceftriaxone decreased lipoteichoic acid
concentrations in cerebrospinal ﬂuid and reduced neuronal
damage compared with the results obtained with treatment
with ceftriaxone alone (14).
In our study, doxycycline moderately antagonized the bac-
tericidal effect of ceftriaxone in vitro, while it had no measur-
able effect on bacterial clearance from CSF in vivo. Therefore,
it appears more likely that the marked protective effect of
doxycycline on several parameters in this model was a result of
its anti-inﬂammatory activity rather than interference with bac-
teriolysis induced by the beta-lactam antibiotic. The anti-in-
ﬂammatory effects of doxycycline include reduction of cytokine
release and inhibition of MMPs (7, 18, 38). We found that
doxycycline also inhibits TACE, whose metalloproteinase do-
main exhibits considerable homology with the MMPs (17). In
bacterial meningitis, MMPs and TACE have multiple roles,
including extracellular matrix digestion and processing of the
proinﬂammatory cytokine TNF- from its inactive membrane-
bound form into its active soluble form (23). Administration of
TNF- into the CSF results in pathophysiologic changes char-
acteristic of bacterial meningitis, including breakdown of the
blood-brain barrier, recruitment of PMNs, and generation of
meningeal inﬂammation (39). A model of sterile meningitis
using hiR6 allowed us to study the effect of doxycycline inde-
pendent of an effect on the killing of live bacteria. In line with
its TACE-inhibiting activity in vitro, doxycycline reduced TNF-
release and reduced the inﬂux of PMNs into the CSF. Further-
more, in an experimental inﬂammatory disease model of the eye,
doxycycline has been shown to reduce interleukin-converting en-
zyme and to decrease the bioactivity of the inﬂammatory cytokine
interleukin-1 beta (41). Thus, the beneﬁcial effect of doxycycline
may at least in part be the result of attenuated inﬂammation.
MMP-mediated BBB disruption contributes to the develop-
ment of global cerebral hypoperfusion by increasing intracra-
nial pressure and brain ischemia (23, 24, 29, 36). In this study,
doxycycline markedly reduced the BBB disruption, which may
explain the beneﬁcial effect of doxycycline therapy on cortical
ischemic brain injury. Sepsis and septic shock are other com-
plications of bacterial meningitis that contribute to the high
mortality (19). In a model of sepsis, tetracycline treatment of
animals reduced the 24-h mortality from 30% to 0% (28).
Similarly, mortality was signiﬁcantly reduced in the present
study by adjuvant therapy with a single dose of doxycycline.
The development of necrotic cortical injury in pneumococ-
cal meningitis involves MMPs and TACE, as documented in
studies using hydroxamate-based inhibitors of MMPs and
TACE, which are active at low (nanomolar) concentrations
(23, 24, 29, 36). In contrast, doxycycline inhibits MMPs at
micromolar concentrations (IC50 for MMP-8, 30 M; IC50 for
MMP-13, 1 M), supporting the notion that the anti-inﬂam-
matory and neuroprotective effect is mediated at least in part
by the inhibition of MMPs and TACE (45). In our study, the
doxycycline concentrations were micromolar in the plasma and
CSF after a dose of 30 mg/kg (approximately 50 M in plasma
and 15 M in CSF). Plasma concentrations of 15 to 20 M
have been reported in humans after an intravenous dose of 200
mg doxycycline (1). Thus, the doxycycline concentrations
found in the present study in infant rats are approximately two-
to threefold higher than the doxycycline concentrations found
in human patients after a therapeutic dose of doxycycline.
Tetracyclines have beneﬁcial effects in other models of brain
injury. In a model of focal central nervous system reperfusion
injury, doxycycline (10 mg/kg every 8 h) signiﬁcantly reduced
the infarct volume (9). In another study, doxycycline (90 mg/kg
every 12 h) and the more lipophilic compound minocycline
protected hippocampal neurons of the CA1 region against
global brain ischemia (49).
Apoptotic neuronal death in the hippocampus is a charac-
teristic feature of pneumococcal meningitis in patients and
corresponding animal models (6, 15, 32). Previous data sug-
gested that MMP-TACE activity plays a role in this form of
injury, since an inhibitor of MMPs and TACE (BB-1101) had
a beneﬁcial effect on both the cortex and the hippocampus
(23). On the other hand, while doxycycline and several other
MMP inhibitors (GM6001 and TNF484) were effective for
preventing cortical injury, they failed to reduce hippocampal
injury (24, 29).
Unilateral or bilateral hearing impairment is the most com-
mon neurologic sequela following meningitis and is found in
up to 30% of patients (34, 47). Hearing loss results from
involvement of the inner ear due to inﬂammation as pneumo-
cocci and leukocytes extend from the CSF to the perilymph via
the cochlear aqueduct (4, 5, 11). In a model of pneumococcal
meningitis the severity of permanent hearing impairment as
assessed by the increase in the ABR thresholds 2 weeks after
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the infection correlated signiﬁcantly with the loss of type I
spiral ganglion neurons (20). The results of the present study
conﬁrm and expand the correlation between the loss of type I
neurons in the spiral ganglion and the degree of hearing im-
pairment in infant rats. Use of adjunctive doxycycline also
resulted in a moderate but signiﬁcant decrease in the ABR
thresholds of infected animals compared to the ABR thresh-
olds of the animals that received only saline. This partial pro-
tection may reﬂect previous damage to the hair cells during the
acute disease, probably caused by factors that adjunctive doxy-
cycline could not attenuate, such as the release of bacterial
pneumolysin in the perilymphatic and endolymphatic spaces
(10, 46). If this is the case, the withdrawal of neurotrophins
normally produced by the hair cells might further aggravate
neuron loss in the spiral ganglion (30). This hypothesis is sup-
ported by the fact that signiﬁcant differences in the neuron
density of the spiral ganglion between infected and mock-
infected animals can only be observed weeks after the cured
infection (20, 37). Together, our results support further inves-
tigation of the beneﬁcial effects of adjunctive doxycycline on
the loss of spiral ganglion neurons caused by bacterial menin-
gitis. This is a very important issue, since for patients, as long
as the neuron density in the spiral ganglion is preserved, co-
chlear implants may still be able to rescue the hearing function.
There may be concerns regarding the use of a beta-lactam
antibiotic in combination with a tetracycline for the treatment
of pneumococcal meningitis. These concerns are based on a
study published in 1951, in which patients with pneumococcal
meningitis who were treated with intramuscular injections of
106 U of penicillin every 2 h were compared with a group of
patients who were treated with a combination of penicillin (106
U every 2 h) plus tetracycline (500 mg every 6 h) (25). The
mortality was signiﬁcantly higher in the penicillin-tetracycline
group (79% versus 30%). A worse outcome for patients with
pneumococcal meningitis who were treated with a penicillin-
tetracycline combination (85% mortality) than for patients
who were treated with penicillin alone (59% mortality) was
also reported in 1961 (33). In contrast, the combination of
ceftriaxone with doxycycline led to an increased survival rate
and had no measurable effect on bacterial clearance in the
present model. Possibly, the bactericidal activity of high doses
of ceftriaxone is more robust against potential antagonism by
doxycycline than the bactericidal activity of moderate doses of
penicillin is. Further preclinical and ultimately clinical studies
are needed to assess whether the combination of ceftriaxone
with doxycycline used in the present study can be used safely
for bacterial meningitis therapy. Importantly, our results
strengthen the concept that inhibition of cytokines and MMPs
is a powerful strategy for adjunctive treatment of pneumococ-
cal meningitis.
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